Xenon Pharmaceuticals Return on Tangible Equity 2012-2022 | XENE

Current and historical return on tangible equity values for Xenon Pharmaceuticals (XENE) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Xenon Pharmaceuticals Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $-0.08B $0.54B -20.28%
2021-12-31 $-0.08B $0.55B -23.12%
2021-09-30 $-0.06B $0.25B -26.86%
2021-06-30 $-0.06B $0.26B -26.19%
2021-03-31 $-0.04B $0.28B -17.60%
2020-12-31 $-0.03B $0.17B -15.34%
2020-09-30 $-0.03B $0.18B -16.59%
2020-06-30 $-0.03B $0.19B -19.85%
2020-03-31 $-0.04B $0.19B -33.79%
2019-12-31 $-0.04B $0.09B -47.95%
2019-09-30 $-0.04B $0.08B -44.19%
2019-06-30 $-0.04B $0.08B -44.22%
2019-03-31 $-0.04B $0.09B -43.70%
2018-12-31 $-0.03B $0.10B -43.69%
2018-09-30 $-0.03B $0.11B -54.87%
2018-06-30 $-0.03B $0.05B -65.82%
2018-03-31 $-0.03B $0.03B -68.79%
2017-12-31 $-0.03B $0.04B -66.67%
2017-09-30 $-0.03B $0.04B -54.21%
2017-06-30 $-0.03B $0.05B -48.33%
2017-03-31 $-0.03B $0.06B -46.09%
2016-12-31 $-0.02B $0.06B -37.70%
2016-09-30 $-0.02B $0.07B -34.85%
2016-06-30 $-0.02B $0.05B -28.81%
2016-03-31 $-0.01B $0.06B -16.19%
2015-12-31 $-0.02B $0.06B -25.40%
2015-09-30 $-0.00B $0.06B -4.55%
2015-06-30 $0.01B $0.06B 8.51%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.548B $0.018B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00